General Session: 360 Degrees of A.I.

sponsored by UnitedHealthcare Dental

Wednesday, September 21

8:30AM – 10:00 AM

Participate in this highly interactive panel session to explore what AI is, and is not, how it impacts utilization management, provider and member experience, and the potential ROI for all stakeholders.

Dr. Joseph Borg
Dental Director, NovoDynamics

Dr. Borg began working as dental director for NovoDynamics in 2021. He is one of the dental insurance industry's foremost experts in utilization management, quality assessment, and regulatory compliance. Before joining NovoDynamics, Dr. Borg served for 20 years in various capacities at Delta Dental of California (DDCA), including its dental director, for the last 11 years. DDCA is one of the largest dental insurers in the US, with more than 22 million enrollees. Before Dr. Borg's tenure with DDCA, he worked in private dental practice. He was granted a California Dental License in 1990 after earning a Doctorate in Dental Surgery (DDS) from the University of Southern California.

Dr. Mary Lee Conicella (moderator)
Chief Dental Officer, Aetna / CVS Health

Dr. Mary Lee Conicella is Aetna’s chief dental officer and oversees dental clinical initiatives, policies, and claim reviews.  She is a member of Aetna’s Medical Affairs Team, focused on driving clinical quality, member engagement, health equity, and improved outcomes.  She has published numerous articles on dental care's impact on holistic health and was instrumental in creating Aetna's groundbreaking Dental-Medical Integration program.  These efforts received global recognition in the National Institutes of Health report: “Oral Health in America: Advances and Challenges.” Dr. Conicella received her DMD from Temple University School of Dentistry and achieved Fellowship status in the Academy of General Dentistry during her private practice.  She spent many years on the University of Pittsburgh School of Dental Medicine faculty and sits on the NYU College of Dentistry Dean’s Strategic Advisory Council. Mary Lee has been a volunteer with NADP since 2006 and is currently serving her second term as a member of the NADP Board of Directors.

Ty Hamilton
Chief Operating Officer, P&R Dental Strategies

Ty is the chief operating officer of P&R Dental Strategies. She is responsible for the day-to-day oversight of the company's operations and informatics activities. Ty has spent over 25 years in medical, dental, vision, and other specialized insurance program operations, where she has successfully managed various commercial and public dental programs and implemented multiple data-driven solutions for quality assurance and quality improvement. Ty has held senior leadership positions with several commercial dental insurance companies, served as the executive director of the Texas Healthy Kids Corporation, and served as the deputy commissioner of the Life/Health Group for the Texas Department of Insurance.

Dr. Wardah Inam
Chief Executive Officer, Overjet

Dr. Wardah Inam is the CEO of Overjet. Overjet is the leading provider of AI technology for the dental industry to help improve patient care. She has been ranked among the 32 most influential people in dentistry by Incisal Edge. Before founding Overjet, she led product development at a healthcare startup, Q Bio, working on biomedical imaging. Before that, she was a Postdoctoral Fellow at MIT Computer Science and Artificial Intelligence Lab, working on remote biomedical sensing using machine learning on wireless signals. Dr. Inam received a Ph.D. from MIT, where she developed AI-powered microgrid technology. This work received widespread recognition, including National Geographic covering it as a breakthrough that could transform how we power the world. She has corporate experience in GE and Apple and is the MIT Graduate Women of Excellence recipient. 

Dr. Ali Sadat 
Chief Executive Officer, Retrace 

Dr. Ali Sadat is the founder and chief executive officer of Retrace. Before founding Retrace, Dr. Sadat maintained clinical and research appointments at the University of California San Francisco and Zuckerberg San Francisco General Hospital, developing novel translational technologies that promote musculoskeletal regeneration by recapitulating development and repair. Using multipotent progenitor cells, biologically modified synthetic scaffolds, and the development of quantitative models, his work aimed to translate these fundamental understandings into clinical application in tissue engineering and regenerative medicine with an emphasis on the craniofacial area. Dr. Sadat believes an interdisciplinary, evidence-based approach is critical for solving our most significant health challenges.